Table 1. Interactions between MPF, MAPK and RhoA on enrichment of actin and myosin during ooplasmic protrusion following different treatments of goat oocytes.
| Treatments | Protrusion | MPF | RhoA | MAPK | Actin enrichment | Myosin enrichment | Spindle integrity |
| D | + | + | + | + | + | + | − |
| D− | − | + | − | − | − | − | − |
| D+U | − | + | + | − | − | − | − |
| D+Y | − | + | − | − | − | − | − |
| D+R | − | − | − | − | − | − | − |
| M | + | + | NA | + | + | + | + |
| M+U | − | + | NA | − | − | − | + |
| M+Y | − | + | − | − | − | − | + |
| M+Y+OA | − | + | − | + | + | − | + |
| M+R | − | − | NA | − | − | − | + |
| OA.5h | − | − | − | + | + | − | + |
| OA4h | + | + | + | + | + | + | + |
| OA4h+R | − | − | − | + | + | − | + |
| OA4h+U | − | − | NA | − | − | − | + |
Abbreviations: D: 0.8 ng/ml demecolcine; D-: Oocytes without protrusion after D; U: 20-µM U0126; Y: 400-µM Y27632; R: 400-µM ROS; M: 5-µM MG132; C: 1-mM caffeine; OA.5h: 0.5-µM OA for 0.5 h; OA4h: 0.1-µM OA for 4 h; +: In the presence of; NA: Not assayed. All treatments were performed for 30 min unless otherwise specified.